Hematol Oncol Clin North Am. 1996 Jun;10(3):727-47.

How is androgen-dependent metastatic prostate cancer best treated?

Source

Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.

Abstract

The principles of management of newly diagnosed metastatic prostate cancer have changed little since the time of Huggins and his colleagues. Modern clinicians have many more weapons in their therapeutic armamentarium than those pioneers, but little progress has been made in improving the survival of men with this disease. The results of androgen deprivation are comparable using any one of a number of different monotherapy approaches. The use of combined androgen blockade may improve survival in men with minimal disease but at considerable economic cost and with significant impairment of quality of life. The benefit of this therapy for men with more extensive disease is uncertain. New modalities such as intermittent androgen blockade or combination therapies are exciting, but unproven.

PMID:: 8773508; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

MD Consult

Medical

Prostate Cancer - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

Review Medical therapy of prostate cancer: 1999. [J S C Med Assoc. 2000]
Review Medical therapy of prostate cancer: 1999.
Afrin LB, Ergul SM. J S C Med Assoc. 2000 Feb; 96(2):77-84.
Review Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. [Evid Rep Technol Assess (Summ)...]
Review Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C, Brown A, Garber A, Gere M, Hasselblad V, et al. Evid Rep Technol Assess (Summ). 1999 May; (4):i-x, 1-246, I1-36, passim.
Review Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. [Cochrane Database Syst Rev. 2002]
Review Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.
Nair B, Wilt T, MacDonald R, Rutks I. Cochrane Database Syst Rev. 2002; (1):CD003506.
Review Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. [Cancer. 2002]
Review Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma.
Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL, Wilt TJ, Aronson N. Cancer. 2002 Jul 15; 95(2):361-76.
Review Treatment options in androgen-independent prostate cancer. [Cancer Invest. 1999]
Review Treatment options in androgen-independent prostate cancer.
Lara PN Jr, Meyers FJ. Cancer Invest. 1999; 17(2):137-44.

See reviews... See all...

Cited by 4 PubMed Central articles

IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. [World J Clin Oncol. 2011]
IL-6/IL-6R as a potential key signaling pathway in prostate cancer development.
Azevedo A, Cunha V, Teixeira AL, Medeiros R. World J Clin Oncol. 2011 Dec 10; 2(12):384-96.
Cancer treatment-related bone loss: a review and synthesis of the literature. [Curr Oncol. 2008]
Cancer treatment-related bone loss: a review and synthesis of the literature.
Khan MN, Khan AA. Curr Oncol. 2008 Jan; 15(Suppl 1):S30-40.
The war on cancer: a report from the front lines. [Proc (Bayl Univ Med Cent). 2006]
The war on cancer: a report from the front lines.
Melmed G. Proc (Bayl Univ Med Cent). 2006 Oct; 19(4):323-34.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

How is androgen-dependent metastatic prostate cancer best treated?
How is androgen-dependent metastatic prostate cancer best treated?
Hematol Oncol Clin North Am. 1996 Jun ;10(3):727-47.

PubMed
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor impairs cell p4fferent...
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor impairs cell p4fferentiation in cultured adipogenic cells (3T3-L1).
Eur J Pharmacol. 1996 Apr 22 ;301(1-3):203-6.

PubMed
Biochemical classification of depression.
Biochemical classification of depression.
Lancet. 1979 Jun 16 ;1(8129):1279-80.

PubMed
Human trehalase: characterization, localization, and its increase in urine by re...
Human trehalase: characterization, localization, and its increase in urine by renal proximal tubular damage.
Nephron. 1996 ;73(2):179-85.

PubMed
Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 ...
Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years.
J Am Coll Cardiol. 1996 Sep ;28(3):616-26.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: